Enanta Pharmaceuticals has begun dosing chronic hepatitis C virus (HCV) patients with its investigational drug EDP-494 as part of a proof-of-concept study designed to demonstrate the medicine’s efficacy in a subset of patients with the chronic infection.
Hepatitis C is a contagious disease caused by the hepatitis C virus, and it is the most common cause of chronic liver disease. Hepatitis C is divided into six major genotypes, according to the genetic structure of the virus. It is important to identify the genotype of HCV, as it may influence the recommended treatment, its dose, and duration. Genotype 1, especially, is the most common type in the U.S. as well as the most difficult to treat.
Most therapies currently on the market act directly on the virus. But due to the high replicating rates of HCV, mutations can occur that render the virus resistant to the therapy.